Bristol Myers Squibb And Hengrui Pharma Announce Up To $15.2B Global Collaboration With $600M Upfront To Advance 13 Early-Stage Oncology And Immunology Programs

Bristol-Myers Squibb

Bristol-Myers Squibb

BMY

0.00

Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide

Agreements include 13 programs with the potential to address significant unmet patient needs and support long‑term growth

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.